What is OptimizeRx's D&A?

OptimizeRx (OPRX) reported D&A of $1.06M in Q1 2026.

How has OptimizeRx's D&A changed year-over-year?

OptimizeRx's D&A decreased by 2.7% year-over-year, from $1.09M to $1.06M.

What is the long-term trend for OptimizeRx's D&A?

Over 3 years (2022 to 2025), OptimizeRx's D&A has grown at a 28.9% compound annual growth rate (CAGR), from $2.02M to $4.33M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

OptimizeRx OPRX D&A

D&A at other companies

Spok HoldingsSPOK

$992K+15.5%

PhreesiaPHR

$3.37M+12.9%

GoodRx Holdings, Inc.GDRX

$21.79M+4.2%

Spectral AI, Inc.MDAI

$30K+1,400%

National Research CorporationNRC

$2.17M+13.8%

Fluent, Inc.FLNT

$1.68M-31.7%

Other financials

Income statement

See full

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

See full

Cash & equivalents$20.2M+21.7%

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

See full

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

See full

Market cap$107.34M-54.1%

Enterprise value$110.88M-55.0%

P/E15.7×—

P/S1×-1.2×

Profitability

See full

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

See full

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OptimizeRx's D&A?: OptimizeRx (OPRX) reported D&A of $1.06M in Q1 2026.
How has OptimizeRx's D&A changed year-over-year?: OptimizeRx's D&A decreased by 2.7% year-over-year, from $1.09M to $1.06M.
What is the long-term trend for OptimizeRx's D&A?: Over 3 years (2022 to 2025), OptimizeRx's D&A has grown at a 28.9% compound annual growth rate (CAGR), from $2.02M to $4.33M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.